FDA Principal Deputy Commissioner Joshua M. Sharfstein, M.D. gave the keynote speech to the Council for Responsible Nutrition Conference yesterday. Dr. Sharfstein expressed a willingness to work with supplement industry members and received a warm welcome from industry members in return.
This is a tale of two types of weight-loss products and how the Food and Drug Administration had different responses to similar problems with them. The separate, but not equivalent treatment raises questions about how the FDA operates.
In the days following the FDA warning on the dangers of taking Hydroxycut and the manufacturer’s recall, the reaction has been more sliced than divided. There were the oft-seen reactions: NaturalNews headlined its commentary, “FDA Floats Hydroxycut Scare to Discredit Yet Another Supplement Company.” The personal injury law firm of Onder Shelton O’Leary & Peterson [...]
The Food & Drug Administration issued on May 1 a consumer warning to stop using Hydroxycut, the heavily marketed weight-loss product. The agency said that “some Hydroxycut products are associated with a number of serious liver injuries” and announced that the maker was recalling all products.
Did the FDA properly react? The warning cited 23 serious [...]
The FDA has just announced a massive recall of the popular weight loss supplement, Hydroxycut.
According to the FDA press release dated today, FDA has received 23 reports of serious health problems ranging from jaundice and elevated liver enzymes, an indicator of potential liver injury, to liver damage requiring liver transplant. One death due to liver [...]
